Clinical trial Recruiting at 1 site Interventional Ages 18 and up

AI-powered vocal monitoring for heart failure home care

Official title: AVATAR-HF (Artificial Voice Analysis and Telemonitoring for Heart Failure): Studio di fattibilità Sull'Uso Dell'Analisi Vocale Basata su Intelligenza Artificiale Per il Telemonitoraggio Dei Pazienti Con Insufficienza Cardiaca.

Run by Niguarda Hospital · NCT07664748 · Data updated 2026-11-12

A feasibility test to see if an AI voice-based home monitoring platform called AVATAR-SC can help people with heart failure manage their condition after hospital discharge.

More Heart Failure trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorNiguarda Hospital
Academic / other
Locations1 site (Milan, Ita)
StatusRecruiting
StartedOctober 30, 2026
Main results expectedMay 15, 2027
Study endsMay 15, 2028
Registry record updatedOctober 13, 2026
Trial IDNCT07664748 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with heart failure (NYHA II-IV), recently discharged after acute heart failure or receiving Levosimendan in a day-hospital setting, who can use the provided device and sign consent in Italian.

Probably not a fit

Patients who cannot interact with the avatar, have significant phonation or cognitive impairments, or have limited life expectancy may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests AVATAR-SC, a home monitoring system that uses voice analysis, simple questionnaires, and AI to flag potential worsening of heart failure. It will enroll 60 adults with heart failure, split between recent post-discharge patients and those receiving Levosimendan in a day-hospital. Participants interact with a computer-generated avatar, submit short voice clips, and complete PROMs to help clinicians monitor status. The trial aims to determine feasibility, user acceptability, and adherence in a real-world home setting. Interventions include AVATAR-SC usage and Levosimendan as applicable within the study design.

Why it matters

Potential benefit: If successful, the platform could make home monitoring easier and more proactive, potentially reducing hospital readmissions for heart failure.

How similar studies have gone: Vocal biomarkers and AI-based monitoring have shown promise in small studies, but robust home-monitoring feasibility data remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Age ≥ 18 years
* Diagnosis of heart failure (NYHA Class II-IV), according to the Diagnosis Related Group (DRG) classification.
* Recent discharge following acute heart failure (AHF) or ongoing treatment with Levosimendan in a Day Hospital setting.
* Provision of signed informed consent in Italian.
* Currently receiving Guideline-Directed Medical Therapy (GDMT) for heart failure

Exclusion Criteria:

* Inability or incapacity to provide informed consent.
* Cognitive impairment severe enough to prevent interaction with the avatar and compromise the reliability of the collected data.
* Significant phonation disorders (e.g., results of previous otorhinolaryngological surgery or post-traumatic outcomes).
* Inability to manage a compatible device or the device provided by the study for interaction with the AVATAR-SC platform.
* Life expectancy of less than 6 months due to concurrent comorbidities.
* Technological or language barriers.

Where it's running

  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, Ita, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.